An interventional study of "HBM-Based Education and Motivational Interviewing" in Human Papillomavirus Infection, sponsored by Saglik Bilimleri Universitesi. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Health services research
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Papillomavirus Infections with a site in Turkey — 1 open to participants now, 2 under way, none of them phase 3. Papillomavirus Infections · Turkey.
Among the 19 studies in Papillomavirus Infections with a site in Turkey, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2024, is one of 15 with no phase, and was the 9th registered.
581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
Browse Papillomavirus Infections studies →1 of the 19 studies in Papillomavirus Infections with a site in Turkey is open now. Recruiting first, the newest first:
Bilecik Seyh Edebali Universitesi · Sites in Turkey
Ages 30–65 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 229 across 406 interventional studies indexed under Papillomavirus Infections.
Median enrollment 90 across the 15 interventional studies, 232 across the 4 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 19 has an industry lead sponsor. The 10 most frequent:
Saglik Bilimleri Universitesi is the lead sponsor of 458 studies on the registry; 124 are open to participants now.
Saglik Bilimleri Universitesi has 1 study filed under Papillomavirus Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Papillomavirus Infections with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07920666Bilecik Seyh Edebali UniversitesiLived Experiences of Women Diagnosed With HPV Infection | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Papillomavirus Infections with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effect of an educational intervention based on the Health Belief Model (HBM) combined with motivational interviewing on women's knowledge about Human Papillomavirus (HPV) infection and their awareness of HPV vaccination. The study will be conducted among women aged 18-45 who have not received the HPV vaccine. Participants in the intervention group will receive structured education and motivational interviews, while the control group will receive no intervention. Changes in HPV knowledge and vaccine awareness will be measured before and after the intervention using validated scales. The goal is to improve preventive behaviors and increase vaccine uptake through behavior-based education.
This randomized controlled trial is designed to assess the impact of education and motivational interviewing grounded in the Health Belief Model (HBM) on women's knowledge regarding HPV and awareness of the HPV vaccine. The study population consists of 18-45-year-old literate women who have not previously received HPV vaccination.
Participants will be randomly assigned to either an intervention group or a control group. The intervention group will receive a 3-session structured education program based on HBM constructs (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, and self-efficacy), supported by motivational interviewing techniques. The control group will receive no intervention.
Data collection will include pre- and post-intervention assessments using a validated HPV knowledge scale and vaccine awareness questionnaire. The expected outcome is a statistically significant improvement in knowledge and awareness in the intervention group.
This study aims to contribute to public health efforts in HPV prevention and vaccination promotion by utilizing a behavioral model in community education.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Voluntary participation and providing
Not previously vaccinated against HPV
Ability to attend all three educational and motivational interview sessions
Literacy sufficient to complete study questionnaires
Exclusion Criteria:
Prior HPV vaccination
Cognitive or psychiatric conditions that hinder participation
Currently participating in another HPV-related education or intervention study
Inability to attend all sessions of the intervention program
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: "HBM-Based Education and Motivational Interviewing"
This group will not receive any educational intervention or motivational interviewing. Standard care or routine health information will be provided as per usual practice.
This intervention consists of a structured 3-session educational program and motivational interviews based on the Health Belief Model (HBM). It aims to increase knowledge about HPV infection and improve HPV vaccination awareness among women aged 18-45.
HPV Knowledge Score
Participants' total score on an HPV knowledge questionnaire designed to assess understanding of HPV infection, transmission, and prevention.
Time frame: 4 weeks after the intervention
HPV Vaccination Awareness Score
Participants' awareness level regarding HPV vaccination, measured using a structured 10-item survey.
Time frame: 4 weeks after the intervention
Plan to share: Yes — IPD and supporting documents will be available starting 6 months after the publication of the primary study results and will remain available for 5 years.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD and supporting documents will be available starting 6 months after the publication of the study results and will remain available for 5 years.
Access criteria: Qualified researchers may request access to the individual participant data by contacting the principal investigator. Access will be granted upon reasonable request and approval of a data sharing agreement.
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Sep 2024, 6 months.
Of 110 non-industry interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 6 months is below that.
Counting every sponsor, half of 119 studies reached it within 26 months; a quarter within 10 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Aug 2025 → Mar 2024, primary completion Sep 2025 → Sep 2024 and completion Dec 2025 → Dec 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi →